

HOSTED BY



ELSEVIER

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/bjbas

Full Length Article

Synthesis and antimicrobial evaluation of certain purine, benzothiazole and thiazole systems substituted with dialkylaminoalkyl-o-cresols

Khaled R.A. Abdellatif^{a,*}, Ghada A. Abd El Wareth^a,
Ossama M. El-Badry^b, Hamdy M. Ragab^b, Mervat M. El-Enany^b

^a Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, 62514, Beni-Suef, Egypt

^b Department of Organic Chemistry, Faculty of Pharmacy, Cairo University, ElKasr Eleini Street, 11562, Cairo, Egypt

ARTICLE INFO

Article history:

Received 22 November 2014

Accepted 16 January 2015

Available online 28 February 2015

Keywords:

Purine

Benzothiazole

Thiazole

o-cresols

Antimicrobial activity

ABSTRACT

Novel series of dialkylaminoalkyl-o-cresols incorporated with purine nucleus **2a–b**, benzothiazole nucleus **5a–b**, **8a–b** and thiazole nucleus **11a–d**, **13a–d** were synthesized through Mannich reaction. Structures of the newly synthesized compounds have been deduced on the basis of elemental analysis and spectral data. Antimicrobial activity evaluation was carried out for all synthesized compounds; most of them exerted comparable activity to ciprofloxacin and flucanazole. The thiazole derivatives **11a**, **13c**, **13d** are the most potent compounds.

Copyright 2015, Beni-Suef University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

The resistance to antimicrobial drugs is widespread; there is an increasing need for identification of novel structure leads that may be of use in designing new, potent and less toxic antimicrobial agents. The previous literature survey revealed that certain phenolic Mannich bases (Magarian and Sorenson, 1976; Pernak et al., 1999), purine (Bakkestuen et al., 2000; Gundersen et al., 2002), benzothiazole (Abdel-Rahman and Morsy, 2007; Hilal et al., 2006; Vicini et al., 2008; Yamazaki et al., 2005) and thiazole (Bozdog-Dundar et al., 2007;

Karegoudar et al., 2008; Ozdemir et al., 2007; Vicini et al., 2006) derivatives exhibited significant antibacterial and anti-fungal activities. At the same time, presence of azo group (Bondock et al., 2007) or azomethine group (Chohan et al., 2003) enhances the antimicrobial activity of the above mentioned nuclei. Also, the introduction of an amidic linkage into the heteroaromatic ring systems increases its biological activity by increasing the lipophilicity of these compounds which facilitates their penetration into the bacterial and fungal cells (Turan-Zitouni et al., 2004, 2005; Zimenkovskii et al., 2006). In view of the aforementioned findings, it was

* Corresponding author. Tel.: +20 100 2535444; fax: +20 082 2317958.

E-mail address: khaled.ahmed@pharm.bsu.edu.eg (K.R.A. Abdellatif).

Peer review under the responsibility of Beni-Suef University.

<http://dx.doi.org/10.1016/j.bjbas.2015.02.008>

2314-8535/Copyright 2015, Beni-Suef University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

interesting to make a link between phenolic Mannich bases and some heteroaromatic ring systems via one of the above pharmacophoric groups. Accordingly and in continuation of our previous work (Abdellatif et al., 2014), we now report combination between purine nucleus with dialkylamino-*o*-cresol moieties via an amidic linkage (2a–b), or an incorporation of a benzothiazole ring system with phenolic Mannich bases through the pharmacophoric azomethine group (5a–b) or via an amidic linkage (8a–b). Moreover, a number of substituted thiazoles incorporated with dialkylamino-*o*-cresol moieties via azo group (11a–d, 13a–d) with the aim that the target compounds may show good antimicrobial activity.

2. Experimental

2.1. Chemistry

2.1.1. General

Melting points were determined on a Griffin apparatus and are uncorrected. Infrared (IR) spectra were recorded on a Shimadzu 435 Spectrometer, using KBr discs and values were represented in cm^{-1} . ^1H NMR spectra were measured on a Varian Gemini 300 MHz spectrometer in CDCl_3 or $\text{DMSO}-d_6$ with TMS as the internal standard. Mass spectra were run on Hewlett Packard 5988 spectrometer. Microanalyses were performed for C, H, N (Micro Analytical Centre, Cairo University, Egypt) and were within $\pm 0.4\%$ of theoretical values. Progress of the reactions was monitored by TLC using TLC sheets pre-coated with UV fluorescent silica gel MERCK 60 F 254 that was visualized by UV lamp. 2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-yl)-*N*-(4-hydroxyphenyl)acetamide (1), 4-benzothiazol-2-yl-phenylamine (3) (Shi et al., 1996), 4-[(4-benzothiazol-2-yl-phenylimino)-methyl]-phenol (4) (Nagarajan et al., 2010), *N*-(4-benzothiazol-2-yl-phenyl)-2-chloroacetamide (6) (Chua et al., 1999; Pan et al., 2013), 4-phenylthiazol-2-ylamine (9a) (Dodson and King, 1945), 4-(4-methylphenyl)thiazol-2-ylamine (9b) (King and Hlavacek, 1950), 2-amino-4-methylthiazole-5-carboxylic acid ethyl ester (9c) (Dodson and King, 1945), 4-(4-phenylthiazol-2-ylazo)phenol (10a), and 2-(4-hydroxy-phenylazo)-4-methylthiazole-5-carboxylic acid ethyl ester (10b) were prepared according to reported procedures.

2.1.1.1. *N*-(3-Diethylaminomethyl-4-hydroxyphenyl)-2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)acetamide (2a). To a solution of the purine derivative 1 (1.64 gm, 5 mmol) in dimethylformamide (15 mL), a mixture of diethylamine (6 mmol) and formaldehyde solution (37–40%) (0.62 mL, 7.5 mmol) in glacial acetic acid (5 mL) was added drop wise. After complete addition, the reaction mixture was stirred at room temperature for 12 h then poured onto ice-cooled water. The formed precipitate was filtered, dried and crystallized from dimethylformamide/water to afford 1.39 g of 2a (67% yield); mp 249–250°; IR (cm^{-1}) 3306, 3257 (OH & NH), 3162, 3086 (CH aromatic), 2984, 2878 (CH aliphatic), 1703, 1651 (amidic C=O), 1555 (C=N), 1518 (C=C aromatic); ^1H NMR ($\text{DMSO}-d_6$) δ 0.95 (t, $J = 7.5$ Hz, 6H, $\text{H}_3\text{C}-\text{H}_2\text{C}-\text{N}-\text{CH}_2-\text{CH}_3$), 2.74 (q, $J = 7.5$ Hz, 4H, $\text{H}_3\text{C}-\text{H}_2\text{C}-\text{N}-\text{CH}_2-\text{CH}_3$), 3.17 (s, 3H, purinyl N3- CH_3), 3.42 (s, 3H, purinyl N1- CH_3), 3.55 (s, 2H, CH_2N); 5.13 (s, 2H, CH_2CO),

6.68–6.72 (m, 2H, phenyl H-2, H-6), 7.35 (d, $J = 8.1$ Hz, 1H, phenyl H-5), 8.04 (s, 1H, purinyl H-8), 9.33 (s, 1H, NH, D_2O exchangeable), 10.17 (s, 1H, OH, D_2O exchangeable); EIMS 414 (M^+). Anal. Calcd for $\text{C}_{20}\text{H}_{26}\text{N}_6\text{O}_4$: C, 57.96; H, 6.32; N, 20.28. Found: C, 58.22; H, 6.29; N, 20.40.

2.1.1.2. 2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-yl)-*N*-[4-hydroxy-3-(4-methylpiperidin-1-ylmethyl)-phenyl]-acetamide (2b). The title compound 2b was synthesized, using a similar procedure to that described for the preparation of 2a, by using 4-methylpiperidine in place of diethylamine, in 80% yield as a pale brown powder; mp 188–190 °C; IR (cm^{-1}) 3300, 3200 (OH & NH), 3160, 3058 (CH aromatic), 2948, 2809 (CH aliphatic), 1705, 1659 (amidic C=O), 1548 (C=N), 1495 (C=C aromatic); ^1H NMR ($\text{DMSO}-d_6$) δ 0.92 (d, $J = 7.2$ Hz, 3H, piperidine CH_3), 1.27–1.43 (m, 5H, piperidiny H-3, H-4, H-5), 2.13 (t, $J = 5.4$ Hz, 4H, piperidiny H-2, H-6), 3.41 (s, 3H, purinyl N3- CH_3), 3.58 (s, 3H, purinyl N1- CH_3), 3.66 (s, 2H, CH_2N), 4.99 (s, 2H, CH_2CO), 6.70–6.73 (m, 2H, phenyl H-2, H-6), 7.33 (d, $J = 8.1$ Hz, 1H, phenyl H-5), 7.77 (s, 1H, purinyl H-8), 9.31 (s, 1H, NH, D_2O exchangeable), 10.41 (s, 1H, OH, D_2O exchangeable); EIMS 441 ($\text{M} + 1$). Anal. Calcd for $\text{C}_{22}\text{H}_{28}\text{N}_6\text{O}_4$: C, 59.99; H, 6.41; N, 19.08. Found: C, 60.14; H, 6.19; N, 18.84.

2.1.1.3. 4-[(4-benzothiazol-2-yl-phenylimino)methyl]-2-dimethylaminomethylphenol (5a). A mixture of dimethylamine (0.005 mol) and formaldehyde solution (37–40%) (0.4 mL, 0.005 mol) in absolute ethanol (5 mL) was added to a solution of 4-[(4-benzothiazol-2-yl-phenylimino)-methyl]-phenol (4) (1.65 gm, 0.005 mol) in absolute ethanol (10 mL). The reaction mixture was heated under reflux for 5 h, allowed to cool to room temperature and poured onto ice cooled water. The formed precipitate was filtered off, dried and crystallized from aqueous ethanol to give 1.94 g of 5a (65% yield); mp 161–163 °C; IR (cm^{-1}) 3420 (OH), 3104, 2955 (CH aromatic), 2924, 2851 (CH aliphatic), 1594 (C=N), 1500 (C=C aromatic); ^1H NMR ($\text{DMSO}-d_6$) δ 2.27 (s, 6H, $\text{H}_3\text{C}-\text{N}-\text{CH}_3$), 3.58 (s, 2H, CH_2N), 7.34–8.12 (m, 12H, phenol H-3, H-5, H-6, phenyl H-2, H-3, H-5, H-6, benzothiazolyl H-4, H-5, H-6, H-7, N=CH), 10.27 (s, 1H, OH, D_2O exchangeable); EIMS 387 (M^+). Anal. Calcd for $\text{C}_{23}\text{H}_{21}\text{N}_3\text{OS}$: C, 71.29; H, 5.46; N, 10.84. Found: C, 70.98; H, 5.29; N, 10.58.

2.1.1.4. 4-[(4-benzothiazol-2-yl-phenylimino)methyl]-2-(piperidin-1-ylmethyl)phenol (5b). The title compound 5b was synthesized, using a similar procedure to that described for the preparation of 5a, by using piperidine in place of dimethylamine, in 62% yield as a pale brown powder; mp 110–112 °C; IR (cm^{-1}) 3420 (OH), 3096, 3027 (CH aromatic), 2932, 2801 (CH aliphatic), 1596 (C=N), 1516 (C=C aromatic); ^1H NMR ($\text{DMSO}-d_6$) δ 1.00–1.12 (m, 6H, piperidine H-3, H-4, H-5), 2.22 (t, 4H, $J = 5.1$ Hz, piperidine H-2, H-6), 3.96 (s, 2H, CH_2N), 7.34–8.12 (m, 12H, phenol H-3, H-5, H-6, phenyl H-2, H-3, H-5, H-6, benzothiazolyl H-4, H-5, H-6, H-7, N=CH), 10.27 (s, 1H, OH, D_2O exchangeable); EIMS 427 (M^+). Anal. Calcd for $\text{C}_{26}\text{H}_{25}\text{N}_3\text{OS}$: C, 73.04; H, 5.89; N, 9.83. Found: C, 73.23; H, 5.73; N, 10.13.

2.1.1.5. *N*-(4-Benzothiazol-2-ylphenyl)-2-(4-hydroxyphenylamino)acetamide (7). A mixture of *N*-(4-benzothiazol-2-ylphenyl)-2-chloroacetamide (6) (1.5 g, 0.005 mol), 4-aminophenol (0.5 g, 0.005 mol) and few crystals

of potassium iodide in absolute ethanol (80 mL) was heated under reflux for 11 h. The formed precipitate was filtered while hot, washed with hot ethanol (5 mL). After drying, the precipitate was suspended in water and neutralized with sodium carbonate solution (20%) then filtered, washed with water, dried and crystallized from n-butanol to afford **7**. m.p. 235–237°, yield: 1.0 g, 53.7%; IR (cm⁻¹) 3424, 3291 (OH & NH), 3102, 3031 (CH aromatic), 2905 (CH aliphatic), 1676 (amidic C=O), 1596 (C=N), 1528 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 4.31 (s, 2H, CH₂C=O), 5.44 (s, 1H, CH₂NH, D₂O exchangeable), 6.50–8.09 (m, 12H, phenol H-2, H-3, H-5, H-6, phenyl H-2, H-3, H-5, H-6, benzothiazolyl H-4, H-5, H-6, H-7), 8.58 (s, 1H, NHCO, D₂O exchangeable), 10.26 (s, 1H, OH, D₂O exchangeable); EIMS 375 (M⁺). Anal. Calcd for C₂₁H₁₇N₃O₂S: C, 67.18; H, 4.56; N, 11.19. Found: C, 66.91; H, 4.59; N, 11.39.

2.1.1.6. N-(4-Benzothiazol-2-ylphenyl)-2-(3-

dimethylaminomethyl-4-hydroxyphenylamino)aceta-mide (**8a**). A mixture of dimethylamine (0.005 mol), formaldehyde solution (37–40%) (0.4 mL, 0.005 mol) and absolute ethanol (5 mL) was added portion wise to a suspension of compound **7** (1.87 g, 0.005 mol) in absolute ethanol (10 mL). The reaction mixture was heated under reflux for 5 h then allowed to cool to room temperature. The obtained precipitate was filtered, dried and crystallized from dimethylformamide/water to give **8a** 1.36 g (63%); mp 209–211 °C; IR (cm⁻¹) 3417, 3275 (OH & NH), 3104, 3054 (CH aromatic), 2919, 2836 (CH aliphatic), 1681 (amidic C=O), 1601 (C=N), 1518 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 2.28 (s, 6H, H₃C–N–CH₃), 3.99 (s, 2H, CH₂N), 4.49 (s, 2H, CH₂CO), 5.41 (s, 1H, CH₂NH, D₂O exchangeable), 6.50–8.14 (m, 11H, hydroxyphenyl H-2, H-5, H-6, phenyl H-2, H-3, H-5, H-6, benzothiazolyl H-4, H-5, H-6, H-7), 8.51 (s, 1H, NHCO, D₂O exchangeable), 10.05 (s, 1H, OH, D₂O exchangeable); EIMS 432 (M⁺). Anal. Calcd for C₂₄H₂₄N₄O₂S: C, 66.64; H, 5.59; N, 12.95. Found: C, 66.40; H, 5.29; N, 12.77.

2.1.1.7. N-(4-Benzothiazol-2-yl-phenyl)-2-[4-hydroxy-3-(4-methylpiperidin-1-ylmethyl)phenyl-amino]acetamide (**8b**). The title compound **8b** was synthesized, using a similar procedure to that described for the preparation of **8a**, by using 4-methylpiperidine in place of dimethylamine, in 69% yield as a pale brown powder; mp 170–172 °C; IR (cm⁻¹) 3420, 3250 (OH & NH), 3103, 3054 (CH aromatic), 2949, 2869 (CH aliphatic), 1694 (amidic C=O), 1601 (C=N), 1519 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 0.92 (d, J = 7.2 Hz, 3H, piperidine CH₃), 1.27–1.43 (m, 5H, piperidine H-3, H-4, H-5), 2.13 (t, 4H, J = 5.4 Hz, piperidine H-2, H-6), 3.66 (s, 2H, CH₂N), 4.49 (s, 2H, CH₂CO), 5.41 (s, 1H, CH₂NH, D₂O exchangeable), 6.50–8.14 (m, 11H, hydroxyphenyl H-2, H-5, H-6, phenyl H-2, H-3, H-5, H-6, benzothiazolyl H-4, H-5, H-6, H-7), 8.51 (s, 1H, NHCO, D₂O exchangeable), 10.05 (s, 1H, OH, D₂O exchangeable); EIMS 486 (M⁺). Anal. Calcd for C₂₈H₃₀N₄O₂S: C, 69.11; H, 6.21; N, 11.51. Found: C, 69.09; H, 5.81; N, 11.67.

2.1.2. General procedure for the preparation of 4-(thiazol-2-ylazo)-2-substituted-methyl-phenol derivatives (**11a–d**)

To a solution of the appropriate azo dye **10a** or **10b** (1.4 g, 0.005 mol) in absolute ethanol (10 mL), a mixture of the respective secondary amine (0.005 mol) and formaldehyde solution (37–40%) (0.4 mL, 0.005 mol) in absolute ethanol

(5 mL) was added. The reaction mixture was heated under reflux for 5 h then set-aside overnight. The solvent was distilled off under reduced pressure. The residue left was dissolved in the least amount of ethanol, precipitated with water, filtered, dried and crystallized from aqueous ethanol to afford the Mannich bases **11a–d**. Physical and spectral data for **11a–d** are listed below.

2.1.2.1. 2-Diethylaminomethyl-4-(4-phenylthiazol-2-ylazo)-phenol (**11a**). Yield, 60%; mp 99–101 °C; IR (cm⁻¹) 3422 (OH), 3105, 2957 (CH aromatic), 2924, 2822 (CH aliphatic), 1596 (C=N), 1543 (N=N), 1501 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 0.96 (t, J = 7.2 Hz, 6H, H₃C–H₂C–N–CH₂–CH₃), 2.74 (q, J = 7.2 Hz, 4H, H₃C–H₂C–N–CH₂–CH₃), 4.04 (s, 2H, CH₂N), 6.76–8.21 (m, 9H, phenol H-2, H-5, H-6, 5 phenyl protons, thiazolyl H-5), 9.87 (s, 1H, OH, D₂O exchangeable); EIMS 366 (M⁺). Anal. Calcd for C₂₀H₂₂N₄O₂S: C, 65.55; H, 6.05; N, 15.29. Found: C, 65.26; H, 5.79; N, 15.55.

2.1.2.2. 2-(4-methylpiperazin-1-ylmethyl)-4-(4-phenylthiazol-2-ylazo) phenol (**11b**). Yield, 51%; mp 179–182 °C; IR (cm⁻¹) 3422 (OH), 3102, 2941 (CH aromatic), 2881, 2824 (CH aliphatic), 1582 (C=N), 1542 (N=N), 1487 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 2.29 (s, 3H, piperazine CH₃), 2.45–2.49 (m, 8H, piperazine H-2, H-3, H-5, H-6), 3.97 (s, 2H, CH₂N), 6.79–8.24 (m, 9H, phenol H-2, H-5, H-6, 5 phenyl protons, thiazolyl H-5), 9.86 (s, 1H, OH, D₂O exchangeable); EIMS 393 (M⁺). Anal. Calcd for C₂₁H₂₃N₅O₂S: C, 64.10; H, 5.89; N, 17.80. Found: C, 64.39; H, 5.71; N, 17.74.

2.1.2.3. 2-(4-Hydroxy-3-piperidin-1-ylmethylphenylazo)-4-methylthiazole-5-carboxylic acid ethyl ester (**11c**). Yield, 66%; mp 87–90 °C; IR (cm⁻¹) 3424 (OH), 3040, 2932 (CH aromatic), 2856, 2808 (CH aliphatic), 1712 (C=O ester), 1602 (C=N), 1583 (N=N), 1522 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 1.0–1.1 (m, 6H, piperidine H-3, H-4, H-5), 1.39 (t, J = 7.2 Hz, 3H, OCH₂CH₃), 2.30 (t, J = 5.4 Hz, 4H, piperidine H-2, H-6), 2.81 (s, 3H, CH₃), 3.75 (s, 2H, CH₂N), 4.36 (q, J = 7.2 Hz, 2H, OCH₂CH₃), 6.94 (d, J = 8.1 Hz, 1H, phenyl H-5), 7.73 (s, 1H, phenyl H-2); 7.91 (d, J = 8.1 Hz, 1H, phenyl H-6), 10.25 (s, 1H, OH, D₂O exchangeable); EIMS 388 (M⁺). Anal. Calcd for C₁₉H₂₄N₄O₃S: C, 58.74; H, 6.23; N, 14.42. Found: C, 58.54; H, 6.62; N, 14.78.

2.1.2.4. 2-(4-hydroxy-3-morpholin-4-ylmethylphenylazo)-4-methylthiazole-5-carboxylic acid ethyl ester (**11d**). Yield, 42%; mp 100–102 °C; IR (cm⁻¹) 3397 (OH), 3040, 2930 (CH aromatic), 2847, 2822 (CH aliphatic), 1712 (C=O ester), 1581 (C=N), 1544 (N=N), 1518 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 1.38 (t, J = 7.2 Hz, 3H, OCH₂CH₃), 2.12 (t, J = 5.7 Hz, 4H, H₂C–N–CH₂ of morpholine moiety), 2.54 (s, 3H, CH₃), 3.98 (s, 2H, CH₂N), 4.37 (q, J = 7.2 Hz, 2H, OCH₂CH₃), 4.68 (t, J = 5.7 Hz, 4H, H₂C–O–CH₂ of morpholine moiety), 6.95 (d, J = 8.1 Hz, 1H, phenyl H-5), 7.74 (s, 1H, phenyl H-2), 7.89 (d, J = 8.1 Hz, 1H, phenyl H-6), 10.23 (s, 1H, OH, D₂O exchangeable); EIMS 390 (M⁺). Anal. Calcd for C₁₈H₂₂N₄O₄S: C, 55.37; H, 5.68; N, 14.35. Found: C, 55.57; H, 5.87; N, 14.25.

2.1.3. General procedure for the preparation of 4-(2-amino-4-substituted-thiazol-5-ylazo) phenols (**12a–b**)

4-aminophenol (1.1 g, 0.01 mol) was dissolved in a mixture of concentrated sulphuric acid (0.7 mL), water (5 mL) and

crushed ice (5 gm) and cooled in ice to 5 °C. A solution of sodium nitrite (0.76 g, 0.011 mol) in water (2 mL) was added drop wise while stirring to the above solution, stirring was continued for further 20 min. The diazonium salt solution was filtered onto a well cooled solution of 4-substituted-thiazol-2-ylamine **9a** or **9b** (0.01 mol) and sodium acetate (2.5 gm, 0.03 mol) in aqueous ethanol (30 mL) and stirred at 5 °C for 2 h. The formed precipitate was filtered, washed well with water, dried and crystallized from the appropriate solvent to yield **12a–b** as orange crystals. Physical and spectral data for **12a–b** are listed below.

2.1.3.1. 4-(2-Amino-4-phenylthiazol-5-ylazo)phenol (**12a**). Yield, 91%; mp 198–200 °C (crystallized from methanol); IR (cm⁻¹): 3486–3333 (OH & NH₂), 3133, 3020 (CH aromatic), 1601 (C=N), 1580 (N=N), 1498 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 5.80 (s, 2H, NH₂, D₂O exchangeable), 6.87–8.18 (m, 9H, 5 phenyl protons and 4 phenol protons), 8.50 (s, 1H, OH, D₂O exchangeable); EIMS 297 (M + 1). Anal. Calcd for C₁₅H₁₂N₄OS: C, 60.79; H, 4.08; N, 18.91. Found: C, 60.89; H, 4.05; N, 18.53.

2.1.3.2. 4-(2-Amino-4-p-tolyl-thiazol-5-ylazo)phenol (**12b**). Yield, 80%; mp 247–248 °C (crystallized from chloroform/diethyl ether); IR (cm⁻¹): 3475, 3345 (OH & NH₂), 3100, 3028 (CH aromatic), 2922, 2853 (CH aliphatic), 1624 (C=N), 1582 (N=N), 1528 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 2.36 (s, 3H, CH₃); 6.85–8.12 (m, 10H, 4 tolyl protons and 4 phenol protons & NH₂ (D₂O exchangeable)), 10.0 (s, 1H, OH, D₂O exchangeable); EIMS 311 (M + 1). Anal. Calcd for C₁₆H₁₄N₄OS: C, 61.92; H, 4.55; N, 18.05. Found: C, 62.08; H, 4.52; N, 17.98.

2.1.4. General procedure for the preparation of 4-(2-amino-4-substituted-thiazol-5-ylazo)-2-substituted-methylphenols (**13a–d**)

To a solution of the thiazole derivative **12a** or **12b** (0.01 mol) in absolute ethanol (10 mL), a mixture of the respective secondary amine (0.01 mol) and formaldehyde solution (37–40%) (0.8 mL, 0.01 mol) in absolute ethanol (5 mL) was added. The reaction mixture was heated under reflux for 5 h then cooled and poured onto ice cooled water. The formed precipitate was filtered, dried and crystallized from aqueous ethanol to afford **13a–d**. Physical and spectral data for **13a–d** are listed below.

2.1.4.1. 4-(2-Amino-4-phenylthiazol-5-ylazo)-2-Diethylaminomethylphenol (**13a**). Yield, 75%; mp 155–158 °C; IR (cm⁻¹) 3374–3284 (OH & NH₂), 3060, 2971 (CH aromatic), 2929, 2862 (CH aliphatic), 1584 (C=N), 1528 (N=N), 1478 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 1.32 (t, J = 7.2 Hz, 6H, CH₂CH₃), 3.84 (s, 2H, CH₂N); 4.28 (q, J = 7.2 Hz, 4H, CH₂CH₃), 6.13 (s, 2H, NH₂, D₂O exchangeable), 6.81–8.13 (m, 8H, 5 phenyl protons and 3 phenol protons), 9.22 (s, 1H, OH, D₂O exchangeable); EIMS 381 (M⁺). Anal. Calcd for C₂₀H₂₃N₅OS: C, 62.97; H, 6.08; N, 18.36. Found: C, 63.11; H, 6.32; N, 18.26.

2.1.4.2. 4-(2-Amino-4-phenylthiazol-5-ylazo)-2-piperidin-1-ylmethylphenol (**13b**). Yield, 62%; mp 145–148 °C; IR (cm⁻¹): 3336–3278 (OH & NH₂), 3060, 2960 (CH aromatic), 2929, 2872 (CH aliphatic), 1595 (C=N), 1516 (N=N), 1477 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 1.01–1.11 (m, 6H, piperidine H-3, H-4, H-5), 2.30 (t, 4H, J = 5.7 Hz, piperidine H-2, H-6), 4.10 (s, 2H, CH₂N);

6.23 (s, 2H, NH₂, D₂O exchangeable); 6.84–8.16 (m, 8H, 5 phenyl protons and 3 phenol protons), 9.18 (s, 1H, OH, D₂O exchangeable); EIMS 393 (M⁺). Anal. Calcd for C₂₁H₂₃N₅OS: C, 64.10; H, 5.89; N, 17.80. Found: C, 64.40; H, 5.91; N, 17.49.

2.1.4.3. 4-(2-Amino-4-p-tolylthiazol-5-ylazo)-2-dimethylaminomethylphenol (**13c**). Yield, 45%; mp 100–102 °C; IR (cm⁻¹): 3312, 3199 (OH & NH₂), 3028, 2972 (CH aromatic), 2925, 2894 (CH aliphatic), 1599 (C=N), 1536 (N=N), 1489 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 2.28 (s, 6H, H₃C–N–CH₃), 2.33 (s, 3H, CH₃), 3.85 (s, 2H, CH₂N), 6.83–8.06 (m, 9H, 4 tolyl protons and 3 phenol protons & NH₂ (D₂O exchangeable)), 10.49 (s, 1H, OH, D₂O exchangeable); EIMS 367 (M⁺). Anal. Calcd for C₁₉H₂₁N₅OS: C, 62.10; H, 5.76; N, 19.06. Found: C, 62.43; H, 5.99; N, 19.00.

2.1.4.4. 4-(2-Amino-4-p-tolyl-thiazol-5-ylazo)-2-morpholin-4-ylmethylphenol (**13d**). Yield, 58%; mp 119–121 °C; IR (cm⁻¹): 3362, 3292 (OH & NH₂), 3066, 2984 (CH aromatic), 2917, 2857 (CH aliphatic), 1589 (C=N), 1535 (N=N), 1488 (C=C aromatic); ¹H NMR (DMSO-d₆) δ 2.13 (t, 4H, J = 5.7 Hz, H₂C–N–CH₂ of morpholine moiety), 2.32 (s, 3H, CH₃), 3.88 (s, 2H, CH₂N), 4.69 (t, 4H, J = 5.7 Hz, H₂C–O–CH₂ of morpholine moiety), 6.86–8.08 (m, 9H, 4 tolyl protons and 3 phenol protons & NH₂ (D₂O exchangeable)), 10.45 (s, 1H, OH, D₂O exchangeable); EIMS 409 (M⁺). Anal. Calcd for C₂₁H₂₃N₅O₂S: C, 61.59; H, 5.66; N, 17.10. Found: C, 61.65; H, 5.37; N, 17.18.

2.2. Antimicrobial evaluation


The antimicrobial activity was determined using the agar dilution technique using ciprofloxacin and fluconazole as positive control and the solvent, dimethylsulfoxide (DMSO) as a negative control according to a previously reported procedure (Lorian, 1980).

3. Results and discussion

3.1. Chemistry

Reacting solution of 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-yl)-N-(4-hydroxyphenyl)acetamide (**1**) in dimethylformamide with a mixture of the appropriate secondary amine (diethylamine or 4-methylpiperidine) and formaldehyde in glacial acetic acid yielded **2a** and **2b** in high yields (67% and 80%) respectively (Scheme 1). The structures of **2a** and **2b** were confirmed on the basis of their elemental and spectral data. The ¹H NMR spectrum of **2a** showed the appearance of a triplet signal at δ 0.95 and a quartet one at δ 2.74 attributed to (H₅C₂–N–C₂H₅) in addition to a singlet at δ 3.55 indicating CH₂N. Also, the ¹H NMR spectrum of **2b** displayed the presence of a doublet peak at δ 0.92 indicating the methyl protons attached to the piperidine moiety, a multiplet peak at δ 1.27–1.43 with 5H integration attributed to piperidine H-3, H-4, H-5, a triplet peak at δ 2.13 with 4H integration attributed to piperidine H-2, H-6, and a singlet signal at δ 3.66 corresponding to CH₂N.

Furthermore, heating equimolar amounts of 4-benzothiazol-2-yl-phenylamine (**3**) with 4-




Scheme 1 – Synthetic protocol for compounds 2a–b. Reagents and conditions: (a) diethylamine or 4-methylpiperidine, formaldehyde, ethanol, reflux, 5 h.


hydroxybenzaldehyde in ethanol containing catalytic amount of glacial acetic acid yielded 4-[(4-benzothiazol-2-yl-phenyl-imino)methyl]phenol (4). Subjecting 4 to Mannich reaction using formaldehyde and secondary amine (dimethylamine or piperidine) in ethanol afforded 5a and 5b as revealed in their 1H NMR spectra which showed singlet at 3.96 or 3.98 ppm assigned to the methylene protons of the CH_2N in addition to signals assigned to the alkylamino groups. Moreover, reacting 3 with chloroacetyl chloride yielded *N*-(4-benzothiazol-2-yl-phenyl)-2-chloroacetamide (6) which upon reaction with 4-aminophenol led to the corresponding acetamide 7. Treating

the latter with formaldehyde and secondary amines (dimethylamine or 4-methylpiperidine) gave the target Mannich bases 8a and 8b (Scheme 2). The 1H NMR spectrum of 8a and 8b showed the characteristic singlet at 3.99 or 3.66 ppm assigned to the methylene protons of the CH_2N in addition to signals assigned to the dimethylamino and 4-methylpiperidino moieties.

On the other hand, the 4-(4-arylthiazol-2-ylazo)phenol (10a, 10b) could be obtained by diazotizing the corresponding starting amines in acetic acid with nitrosyl sulphuric acid. Reacting the phenolic azo dye 10a, 10b with formaldehyde



Scheme 2 – Synthetic protocol for compounds 5a–b and 8a–b. Reagents and conditions. (a) 4-hydroxybenzaldehyde, ethanol, acetic acid, 20 h; (b) dimethylamine or piperidine for 4 and dimethylamine or 4-methylpiperidine for 7, formaldehyde, ethanol, reflux, 5 h; (c) chloroacetyl chloride, benzene, reflux, 30 min; (d) 4-aminophenol, potassium iodide, ethanol, reflux 11 h.



Scheme 3 – Synthetic protocol for compounds 11a–d and 13a–d. Reagents and conditions: (a) i- NaNO₂, H₂SO₄, acetic acid, 5 °C, 2 h, ii-phenol, NaOH, 5 °C, 2 h; (b) diethylamine or 4-methylpiperazine for 10a, piperidine or morpholine for 10b, diethylamine or piperidine for 12a and dimethylamine, or morpholine for 12b, formaldehyde, ethanol, reflux, 5 h; (c) sodium acetate, ethanol, 5 °C, 2 h.

and secondary amine (diethylamine, 4-methylpiperazine, piperidine or morpholine) in ethanol afforded the target compounds 11a–d. The ¹H NMR spectrum of 11a–d showed the characteristic singlet at 3.75–4.04 ppm assigned to the methylene protons of the CH₂N in addition to signals assigned to the diethylamino, 4-methylpiperazino, piperidino and morpholino moieties. Moreover, reacting 4-substituted-thiazole-2-ylamine 9a, 9b with *p*-aminophenol diazonium salt solution in presence of sodium acetate yielded the corresponding azo phenols 12a, 12b in high yields (80% and 91% respectively). The reaction of 12a, 12b according to Mannich reaction conditions with the appropriate secondary amine (diethylamine, piperidine, dimethylamine or morpholine) yielded the target compounds 13a–d (Scheme 3). The ¹H-NMR spectrum of 13a–d showed the characteristic singlet at

3.84–4.10 ppm assigned to the methylene protons of the CH₂N in addition to signals assigned to the diethylamino, piperidino, dimethylamino or morpholino groups.

3.2. Pharmacological screening

The antimicrobial activity of the synthesized compounds 2a–b, 5a–b, 8a–b, 11a–d, and 13a–d was studied using the agar dilution technique using ciprofloxacin and fluconazole as positive control and the solvent, dimethylsulfoxide (DMSO) as a negative control. The synthesized compounds were screened for their *in vitro* antimicrobial testing using six selected standard isolates as a representative examples of different types of microorganisms as follows: gram-positive both non sporulated bacteria as *Staphylococcus aureus* and

Table 1 – MIC ($\mu\text{g/mL}$) of heterocyclic systems substituted with dialkylaminoalkyl-*o*-cresols.

Comp no.	<i>Ps. aeruginosa</i>	<i>E. coli</i>	<i>B. subtilis</i>	<i>S. aureus</i>	MRSA	<i>C. albicans</i>
2a	>800	>800	>800	>800	>800	>800
2b	>800	>800	>800	>800	>800	>800
5a	>800	800	50	50	50	50
5b	>800	>800	>800	>800	>800	>800
8a	>800	800	200	50	50	200
8b	>800	>800	800	100	100	200
11a	>800	800	12.5	12.5	12.5	800
11b	>800	800	25	25	25	25
11c	>800	800	400	200	200	12.5
11d	>800	>800	>800	>800	>800	>800
13a	>800	400	25	25	25	400
13b	>800	400	50	200	200	>800
13c	>800	200	12.5	12.5	12.5	12.5
13d	>800	400	12.5	12.5	12.5	>800
DMSO	>800	>800	>800	>800	>800	>800
Ciprofloxacin	<6.25	50	<6.25	<6.25	12.5	400
Fluconazole	>800	>800	>800	>800	>800	6.25

micithillin resistant *Staphylococcus aureus* (MRSA), sporulated as *Bacillus subtilis*, gram-negative bacteria both sensitive as *Escherichia coli*, resistant as *Pseudomonas aeruginosa* and a fungus as *Candida albicans*. The results are recorded in Table 1 and it was clear that there is variability in the susceptibilities of the different organisms to the different tested compounds. Gram-negative bacteria were the most resistant organism while gram-positive bacteria were the most sensitive. Some compounds showed both antibacterial and antifungal activity, while others showed antibacterial activity with no antifungal activity and vice versa. Compound 13c showed the highest activity against gram-positive and gram-negative bacteria and fungi, also compound 5a showed a potent activity against both gram-positive bacteria and fungi. Compounds 11a, 13a and 13d have a significant activity against gram-positive bacteria and no activity against fungi. A moderate activity against gram-positive bacteria and fungi was shown by compound 8a and 11b.

4. Conclusion

We can conclude that the combination of phenolic Mannich bases with a thiazole ring system via azo group (11a, 13a, 13b, 13c) showed a potent antimicrobial activity while the incorporation of benzothiazole nucleus with alkylamino-*o*-cresols through an amidic linkage (8a) exhibited a moderate antimicrobial activity. On the other hand, the incorporation of Mannich bases with purine nucleus (2a–b) resulted in products with no antimicrobial activity.

REFERENCES

- Abdel-Rahman HM, Morsy MA. Novel benzothiazolyl urea and thiourea derivatives with potential cytotoxic and antimicrobial activities. *J Enzyme Inhib Med Chem* 2007;22:57–64.
- Abdellatif KR, Abdelall EK, Abdelgawad MA, Ahmed RR, Bakr RB. Synthesis and anticancer activity of some new pyrazolo[3,4-d]pyrimidin-4-one derivatives. *Molecules* 2014;19:3297–309.
- Bakkestuen AK, Gundersen LL, Langli G, Liu F, Nolsoe JM. 9-benzylpurines with inhibitory activity against *Mycobacterium tuberculosis*. *Bioorg Med Chem Lett* 2000;10:1207–10.
- Bondock S, Khalifa W, Fadda AA. Synthesis and antimicrobial evaluation of some new thiazole, thiazolidinone and thiazoline derivatives starting from 1-chloro-3,4-dihydronaphthalene-2-carboxaldehyde. *Eur J Med Chem* 2007;42:948–54.
- Bozdog-Dundar O, Ozgen O, Mentese A, Altanlar N, Atli O, Kendi E, et al. Synthesis and antimicrobial activity of some new thiazolyl thiazolidine-2,4-dione derivatives. *Bioorg Med Chem* 2007;15:6012–7.
- Chohan ZH, Scozzafava A, Supuran CT. Zinc complexes of benzothiazole-derived Schiff bases with antibacterial activity. *J Enzyme Inhib Med Chem* 2003;18:259–63.
- Chua MS, Shi DF, Wrigley S, Bradshaw TD, Hutchinson I, Shaw PN, et al. Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylamino-phenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines. *J Med Chem* 1999;42:381–92.
- Dodson RM, King LC. The reaction of ketones with halogens and thiourea. *J Am Chem Soc* 1945;67:2242.
- Gundersen LL, Nissen-Meyer J, Spilberg B. Synthesis and antimycobacterial activity of 6-aryl-purines: the requirements for the N-9 substituent in active antimycobacterial purines. *J Med Chem* 2002;45:1383–6.
- Hilal HS, Ali-Shtayeh MS, Arafat R, Al-Tel T, Voelter W, Barakat A. Synthesis of a new series of heterocyclic scaffolds for medicinal purposes. *Eur J Med Chem* 2006;41:1017–24.
- Karegoudar P, Karthikeyan MS, Prasad DJ, Mahalinga M, Holla BS, Kumari NS. Synthesis of some novel 2,4-disubstituted thiazoles as possible antimicrobial agents. *Eur J Med Chem* 2008;43:261–7.
- King LC, Hlavacek RJ. The reaction of ketones with iodine and thiourea. *J Am Chem Soc* 1950;72:3722–5.
- Lorian V. *Antibiotics in laboratory Medicine*. edn. Baltimore London: Williams and Wilkins; 1980.
- Magarian RA, Sorenson WG. Adamantanamine derivatives. Antimicrobial activities of certain Mannich bases. *J Med Chem* 1976;19:186–9.
- Nagarajan AS, Kathirvelan D, Pramesh M, Reddy BSR. Synthesis of benzothiazole appended -lactams through [2+2]-

- cycloaddition reaction. *Org Chem Incl Med Chem* 2010;49B:1662–6.
- Ozdemir A, Turan-Zitouni G, Kaplancikli ZA, Revial G, Guven K. Synthesis and antimicrobial activity of 1-(4-aryl-2-thiazolyl)-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives. *Eur J Med Chem* 2007;42:403–9.
- Pan J, Mason NS, Debnath ML, Mathis CA, Klunk WE, Lin KS. Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as beta-amyloid plaque binding agents. *Bioorg Med Chem Lett* 2013;23:1720–6.
- Pernak J, Mirska I, Kmiecik R. Antimicrobial activities of new analogues of benzalkonium chloride. *Eur J Med Chem* 1999;34:765–71.
- Shi DF, Bradshaw TD, Wrigley S, McCall CJ, Lelieveld P, Fichtner I, et al. Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. *J Med Chem* 1996;39:3375–84.
- Turan-Zitouni G, Demirayak S, Ozdemir A, Kaplancikli ZA, Yildiz MT. Synthesis of some 2-[(benzazole-2-yl)thioacetylamino]thiazole derivatives and their antimicrobial activity and toxicity. *Eur J Med Chem* 2004;39:267–72.
- Turan-Zitouni G, Kaplancikli ZA, Yildiz MT, Chevallet P, Kaya D. Synthesis and antimicrobial activity of 4-phenyl/cyclohexyl-5-(1-phenoxyethyl)-3-[N-(2-thiazolyl)acetamido]thio-4H-1,2,4-triazole derivatives. *Eur J Med Chem* 2005;40:607–13.
- Vicini P, Geronikaki A, Anastasia K, Incerti M, Zani F. Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones. *Bioorg Med Chem* 2006;14:3859–64.
- Vicini P, Geronikaki A, Incerti M, Zani F, Dearden J, Hewitt M. 2-heteroarylimino-5-benzylidene-4-thiazolidinones analogues of 2-thiazolylimino-5-benzylidene-4-thiazolidinones with antimicrobial activity: synthesis and structure-activity relationship. *Bioorg Med Chem* 2008;16:3714–24.
- Yamazaki K, Kaneko Y, Suwa K, Ebara S, Nakazawa K, Yasuno K. Synthesis of potent and selective inhibitors of *Candida albicans* N-myristoyltransferase based on the benzothiazole structure. *Bioorg Med Chem* 2005;13:2509–22.
- Zimenkovskii BS, Kutsyk RV, Lesyk RB, Matyichuk VS, Obushak ND, Klyufinska TI. Synthesis and antimicrobial activity of 2,4-dioxothiazolidine-5-acetic acid amides. *Pharm Chem J* 2006;40:303–6.